MedTrace Logo

Jaktinib Hydrochloride Cream For Atopic Dermatitis

NCT04435392 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2024-04-02

No results posted yet for this study

Summary

This study includes a dose escalation part and a dose extension part.

Conditions

Interventions

DRUG

Jaktinib Hydrochloride Cream

Subjects in each group were scheduled to give the drug for 8 weeks.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Qianjin Lu, PhD · Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-14
Primary Completion
2022-09-08
Completion
2022-09-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435392 on ClinicalTrials.gov